EligibleTrials

Clinical trials recruiting for Metastatic Malignant Neoplasm in the Peritoneum

Fewer than 3 recruiting trials found.

2
Recruiting trials
4
US states with sites
1
Countries
0%
Accept healthy volunteers

Phase breakdown

Phase 1 1Phase 2 1

Drugs and treatments being studied

InterventionTrials
Cisplatin2
Doxorubicin1
Fluorouracil1
Hyperthermic intraperitoneal chemotherapy1
Irinotecan1
Leucovorin1
Mitomycin1
Nab-paclitaxel1
Oxaliplatin1

Where trials are recruiting (top US states)

StateRecruiting trials
California1
Florida1
Minnesota1
New York1

Top cities

Duarte, California 1Greenlawn, New York 1Jacksonville, Florida 1Rochester, Minnesota 1

Self-screener

Recruiting trials

Related conditions

Trials recruiting for Metastatic Malignant Neoplasm in the Peritoneum often also study these conditions. Each links to its own recruiting-trial list.

Stage IVC Colorectal Cancer AJCC v8 7Stage IVB Uterine Corpus Cancer AJCC v8 4Stage IVB Ovarian Cancer AJCC v8 3Stage IVB Colorectal Cancer AJCC v8 7Stage IVA Uterine Corpus Cancer AJCC v8 4Stage IVA Ovarian Cancer AJCC v8 3Stage IVA Colorectal Cancer AJCC v8 7Stage IV Uterine Corpus Cancer AJCC v8 3Stage IV Pancreatic Cancer AJCC v8 19Stage IV Ovarian Cancer AJCC v8 4

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Metastatic Malignant Neoplasm in the Peritoneum trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.